LifeStance Health Group, Inc. (NASDAQ:LFST) Short Interest Down 10.1% in December

LifeStance Health Group, Inc. (NASDAQ:LFST) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totalling 9,860,000 shares, a drop of 10.1% from the December 15th total of 10,970,000 shares. Approximately 8.9% of the shares of the company are short sold. Based on an average daily volume of 1,460,000 shares, the short-interest ratio is currently 6.8 days.

LifeStance Health Group Stock Up 0.1 %

LFST traded up $0.01 on Friday, hitting $7.99. The company had a trading volume of 1,158,246 shares, compared to its average volume of 1,078,520. LifeStance Health Group has a 52-week low of $4.64 and a 52-week high of $9.20. The stock has a fifty day simple moving average of $7.44 and a 200-day simple moving average of $6.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.32 and a quick ratio of 1.32. The firm has a market capitalization of $3.06 billion, a P/E ratio of -30.73 and a beta of 1.26.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The business had revenue of $312.70 million for the quarter, compared to analysts’ expectations of $302.25 million. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.66%. The business’s revenue was up 18.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.17) earnings per share. As a group, equities analysts expect that LifeStance Health Group will post -0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Barclays raised their price objective on LifeStance Health Group from $6.00 to $7.00 and gave the company an “underweight” rating in a report on Monday, November 11th. The Goldman Sachs Group raised shares of LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Monday, December 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, LifeStance Health Group currently has an average rating of “Hold” and an average target price of $8.70.

Insider Transactions at LifeStance Health Group

In other LifeStance Health Group news, Director Robert Bessler sold 75,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $7.54, for a total value of $565,500.00. Following the sale, the director now directly owns 1,424,447 shares in the company, valued at $10,740,330.38. This represents a 5.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LFST. Algert Global LLC purchased a new position in shares of LifeStance Health Group during the second quarter valued at approximately $57,000. Victory Capital Management Inc. raised its stake in LifeStance Health Group by 27.0% during the 2nd quarter. Victory Capital Management Inc. now owns 14,407 shares of the company’s stock valued at $71,000 after buying an additional 3,063 shares during the last quarter. Park Edge Advisors LLC bought a new position in shares of LifeStance Health Group during the 3rd quarter valued at $73,000. Townsquare Capital LLC purchased a new position in shares of LifeStance Health Group in the 3rd quarter worth $73,000. Finally, Dark Forest Capital Management LP purchased a new position in shares of LifeStance Health Group in the 2nd quarter worth $81,000. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.